Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease.

Dukinfield M, Maniati E, Reynolds LE, Aubdool A, Baliga RS, D'Amico G, Maiques O, Wang J, Bedi KC Jr, Margulies KB, Sanz-Moreno V, Hobbs A, Hodivala-Dilke K.

J Pathol. 2019 Aug 19. doi: 10.1002/path.5340. [Epub ahead of print]

PMID:
31424556
2.

Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861.

Pedrosa AR, Bodrug N, Gomez-Escudero J, Carter EP, Reynolds LE, Georgiou PN, Fernandez I, Lees DM, Kostourou V, Alexopoulou AN, Batista S, Tavora B, Serrels B, Parsons M, Iskratsch T, Hodivala-Dilke KM.

Cancer Res. 2019 Sep 1;79(17):4371-4386. doi: 10.1158/0008-5472.CAN-18-3934. Epub 2019 Jun 12.

PMID:
31189647
3.

Single-cell transcriptome analyses reveal novel targets modulating cardiac neovascularization by resident endothelial cells following myocardial infarction.

Li Z, Solomonidis EG, Meloni M, Taylor RS, Duffin R, Dobie R, Magalhaes MS, Henderson BEP, Louwe PA, D'Amico G, Hodivala-Dilke KM, Shah AM, Mills NL, Simons BD, Gray GA, Henderson NC, Baker AH, Brittan M.

Eur Heart J. 2019 Aug 7;40(30):2507-2520. doi: 10.1093/eurheartj/ehz305.

4.

C-type natriuretic peptide co-ordinates cardiac structure and function.

Moyes AJ, Chu SM, Aubdool AA, Dukinfield MS, Margulies KB, Bedi KC, Hodivala-Dilke K, Baliga RS, Hobbs AJ.

Eur Heart J. 2019 Mar 21. pii: ehz093. doi: 10.1093/eurheartj/ehz093. [Epub ahead of print]

PMID:
30903134
5.

A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.

Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A, Gadaleta E, Rhys HI, Kennedy PT, Hermida MA, Chang TY, Shaw PE, Reynolds LE, McKay TR, Wang HW, Ribeiro PS, Plevin MJ, Lagos D, Lemoine NR, Rajan P, Graham TA, Chelala C, Hodivala-Dilke KM, Spendlove I, Sharp TV.

EMBO Mol Med. 2018 Aug;10(8). pii: e8304. doi: 10.15252/emmm.201708304.

6.

Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.

Weinmüller M, Rechenmacher F, Kiran Marelli U, Reichart F, Kapp TG, Räder AFB, Di Leva FS, Marinelli L, Novellino E, Muñoz-Félix JM, Hodivala-Dilke K, Schumacher A, Fanous J, Gilon C, Hoffman A, Kessler H.

Angew Chem Int Ed Engl. 2017 Dec 18;56(51):16405-16409. doi: 10.1002/anie.201709709. Epub 2017 Nov 23.

PMID:
29072809
7.

Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium-specific FAK-kinase dead mice.

Alexopoulou AN, Lees DM, Bodrug N, Lechertier T, Fernandez I, D'Amico G, Dukinfield M, Batista S, Tavora B, Serrels B, Hodivala-Dilke K.

J Pathol. 2017 Jul;242(3):358-370. doi: 10.1002/path.4911. Epub 2017 Jun 1.

8.

Dual role of pericyte α6β1-integrin in tumour blood vessels.

Reynolds LE, D'Amico G, Lechertier T, Papachristodoulou A, Muñoz-Félix JM, De Arcangelis A, Baker M, Serrels B, Hodivala-Dilke KM.

J Cell Sci. 2017 May 1;130(9):1583-1595. doi: 10.1242/jcs.197848. Epub 2017 Mar 13.

9.

Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment.

Wong PP, Bodrug N, Hodivala-Dilke KM.

Curr Biol. 2016 Nov 7;26(21):R1161-R1166. doi: 10.1016/j.cub.2016.09.043. Review.

10.

Endothelial FAK is required for tumour angiogenesis.

Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM.

EMBO Mol Med. 2016 Oct 4;8(10):1229. doi: 10.15252/emmm.201606907. Print 2016 Oct. No abstract available.

11.

αvβ3 Integrin and tumour blood vessels-learning from the past to shape the future.

Demircioglu F, Hodivala-Dilke K.

Curr Opin Cell Biol. 2016 Oct;42:121-127. doi: 10.1016/j.ceb.2016.07.008. Epub 2016 Jul 27. Review.

PMID:
27474973
12.

Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma.

Di Maggio F, Arumugam P, Delvecchio FR, Batista S, Lechertier T, Hodivala-Dilke K, Kocher HM.

Pancreatology. 2016 Nov - Dec;16(6):995-1004. doi: 10.1016/j.pan.2016.05.393. Epub 2016 Jun 1.

13.

Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.

Roy-Luzarraga M, Hodivala-Dilke K.

Clin Cancer Res. 2016 Aug 1;22(15):3718-24. doi: 10.1158/1078-0432.CCR-14-2021. Epub 2016 Jun 4. Review.

14.

A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.

Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Lebras M, Burns AJ, Saunders NJ, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A, Salomoni P.

Clin Cancer Res. 2016 Jul 1;22(13):3398-409. doi: 10.1158/1078-0432.CCR-15-2081. Epub 2016 Apr 13. Erratum in: Clin Cancer Res. 2017 Feb 1;23 (3):870.

15.

Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC.

Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kähäri VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O'Toole EA.

J Natl Cancer Inst. 2015 Oct 16;108(1). pii: djv293. doi: 10.1093/jnci/djv293. Print 2016 Jan.

PMID:
26476432
16.

Interleukin-6 Stimulates Defective Angiogenesis.

Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR, Balkwill F.

Cancer Res. 2015 Aug 1;75(15):3098-107. doi: 10.1158/0008-5472.CAN-15-1227. Epub 2015 Jun 16.

17.

Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.

Wong PP, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MR, Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S, Elia G, Hagemann T, Kocher HM, Hodivala-Dilke KM.

Cancer Cell. 2015 Jan 12;27(1):123-37. doi: 10.1016/j.ccell.2014.10.015.

18.

The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling.

Birdsey GM, Shah AV, Dufton N, Reynolds LE, Osuna Almagro L, Yang Y, Aspalter IM, Khan ST, Mason JC, Dejana E, Göttgens B, Hodivala-Dilke K, Gerhardt H, Adams RH, Randi AM.

Dev Cell. 2015 Jan 12;32(1):82-96. doi: 10.1016/j.devcel.2014.11.016.

19.

Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.

Batista S, Maniati E, Reynolds LE, Tavora B, Lees DM, Fernandez I, Elia G, Casanovas O, Lo Celso C, Hagemann T, Hodivala-Dilke K.

Nat Commun. 2014 Oct 1;5:5054. doi: 10.1038/ncomms6054.

PMID:
25270220
20.

Generation of point-mutant FAK knockin mice.

Tavora B, Batista S, Alexopoulou AN, Kostourou V, Fernandez I, Robinson SD, Lees DM, Serrels B, Hodivala-Dilke K.

Genesis. 2014 Nov;52(11):907-15. doi: 10.1002/dvg.22823. Epub 2014 Sep 30.

PMID:
25242698
21.

Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.

Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong PP, Alexopoulou A, Elia G, Clear A, Ledoux A, Hunter J, Perkins N, Gribben JG, Hodivala-Dilke KM.

Nature. 2014 Oct 2;514(7520):112-6. doi: 10.1038/nature13541. Epub 2014 Jul 27.

22.

Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.

Alexopoulou AN, Ho-Yen CM, Papalazarou V, Elia G, Jones JL, Hodivala-Dilke K.

BMC Cancer. 2014 Apr 2;14:237. doi: 10.1186/1471-2407-14-237.

23.

Fascin 1 is dispensable for developmental and tumour angiogenesis.

Ma Y, Reynolds LE, Li A, Stevenson RP, Hodivala-Dilke KM, Yamashiro S, Machesky LM.

Biol Open. 2013 Sep 19;2(11):1187-91. doi: 10.1242/bio.20136031. eCollection 2013.

24.

Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice.

Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD.

Circ Res. 2014 Jan 3;114(1):79-91. doi: 10.1161/CIRCRESAHA.114.301591. Epub 2013 Oct 8.

PMID:
24103390
25.

FAK-heterozygous mice display enhanced tumour angiogenesis.

Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones DT, Tavora B, Ramjaun AR, Birdsey GM, Robinson SD, Parsons M, Randi AM, Hart IR, Hodivala-Dilke K.

Nat Commun. 2013;4:2020. doi: 10.1038/ncomms3020.

26.

Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.

Martino-Echarri E, Fernández-Rodríguez R, Rodríguez-Baena FJ, Barrientos-Durán A, Torres-Collado AX, Plaza-Calonge Mdel C, Amador-Cubero S, Cortés J, Reynolds LE, Hodivala-Dilke KM, Rodríguez-Manzaneque JC.

Int J Cancer. 2013 Nov 15;133(10):2315-24. doi: 10.1002/ijc.28271. Epub 2013 Jun 13.

27.

Stromal Claudin14-heterozygosity, but not deletion, increases tumour blood leakage without affecting tumour growth.

Baker M, Reynolds LE, Robinson SD, Lees DM, Parsons M, Elia G, Hodivala-Dilke K.

PLoS One. 2013 May 13;8(5):e62516. doi: 10.1371/journal.pone.0062516. Print 2013.

28.

Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice.

Jones DT, Lechertier T, Reynolds LE, Mitter R, Robinson SD, Kirn-Safran CB, Hodivala-Dilke KM.

Dis Model Mech. 2013 Jan;6(1):115-24. doi: 10.1242/dmm.009183. Epub 2012 Nov 1.

29.

Gene expression analysis in human breast cancer associated blood vessels.

Jones DT, Lechertier T, Mitter R, Herbert JM, Bicknell R, Jones JL, Li JL, Buffa F, Harris AL, Hodivala-Dilke K.

PLoS One. 2012;7(10):e44294. doi: 10.1371/journal.pone.0044294. Epub 2012 Oct 2.

30.

Use of the mouse aortic ring assay to study angiogenesis.

Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K.

Nat Protoc. 2011 Dec 22;7(1):89-104. doi: 10.1038/nprot.2011.435.

PMID:
22193302
31.

Focal adhesion kinase and tumour angiogenesis.

Lechertier T, Hodivala-Dilke K.

J Pathol. 2012 Jan;226(2):404-12. doi: 10.1002/path.3018. Epub 2011 Nov 23. Review.

PMID:
21984450
32.

Measuring angiogenesis in mice.

Tavora B, Batista S, Hodivala-Dilke K.

Methods Mol Biol. 2011;769:351-8. doi: 10.1007/978-1-61779-207-6_23.

PMID:
21748687
33.

The role of β3-integrins in tumor angiogenesis: context is everything.

Robinson SD, Hodivala-Dilke KM.

Curr Opin Cell Biol. 2011 Oct;23(5):630-7. doi: 10.1016/j.ceb.2011.03.014. Epub 2011 May 10. Review.

PMID:
21565482
34.

Endothelial FAK is required for tumour angiogenesis.

Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM.

EMBO Mol Med. 2010 Dec;2(12):516-28. doi: 10.1002/emmm.201000106. Erratum in: EMBO Mol Med. 2016 Oct 4;8(10 ):1229.

35.

Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF.

da Silva RG, Tavora B, Robinson SD, Reynolds LE, Szekeres C, Lamar J, Batista S, Kostourou V, Germain MA, Reynolds AR, Jones DT, Watson AR, Jones JL, Harris A, Hart IR, Iruela-Arispe ML, Dipersio CM, Kreidberg JA, Hodivala-Dilke KM.

Am J Pathol. 2010 Sep;177(3):1534-48. doi: 10.2353/ajpath.2010.100043. Epub 2010 Jul 16.

36.

Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.

Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM.

Nature. 2010 Jun 10;465(7299):813-7. doi: 10.1038/nature09106. Erratum in: Nature. 2010 Jul 15;466(7304):398.

37.

Alpha v beta3 integrin spatially regulates VASP and RIAM to control adhesion dynamics and migration.

Worth DC, Hodivala-Dilke K, Robinson SD, King SJ, Morton PE, Gertler FB, Humphries MJ, Parsons M.

J Cell Biol. 2010 Apr 19;189(2):369-83. doi: 10.1083/jcb.200912014.

38.

Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.

D'Amico G, Robinson SD, Germain M, Reynolds LE, Thomas GJ, Elia G, Saunders G, Fruttiger M, Tybulewicz V, Mavria G, Hodivala-Dilke KM.

PLoS One. 2010 Mar 22;5(3):e9766. doi: 10.1371/journal.pone.0009766.

39.

Deficiency of bone marrow beta3-integrin enhances non-functional neovascularization.

Watson AR, Pitchford SC, Reynolds LE, Direkze N, Brittan M, Alison MR, Rankin S, Wright NA, Hodivala-Dilke KM.

J Pathol. 2010 Mar;220(4):435-45. doi: 10.1002/path.2660.

PMID:
19967726
40.

Genetic ablation of the alpha 6-integrin subunit in Tie1Cre mice enhances tumour angiogenesis.

Germain M, De Arcangelis A, Robinson SD, Baker M, Tavora B, D'Amico G, Silva R, Kostourou V, Reynolds LE, Watson A, Jones JL, Georges-Labouesse E, Hodivala-Dilke K.

J Pathol. 2010 Feb;220(3):370-81. doi: 10.1002/path.2654.

PMID:
19967723
41.

Regulation of lymphatic-blood vessel separation by endothelial Rac1.

D'Amico G, Jones DT, Nye E, Sapienza K, Ramjuan AR, Reynolds LE, Robinson SD, Kostourou V, Martinez D, Aubyn D, Grose R, Thomas GJ, Spencer-Dene B, Zicha D, Davies D, Tybulewicz V, Hodivala-Dilke KM.

Development. 2009 Dec;136(23):4043-53. doi: 10.1242/dev.035014. Erratum in: Development. 2010 Jan;137(2):359.

42.

Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis.

Robinson SD, Reynolds LE, Kostourou V, Reynolds AR, da Silva RG, Tavora B, Baker M, Marshall JF, Hodivala-Dilke KM.

J Biol Chem. 2009 Dec 4;284(49):33966-81. doi: 10.1074/jbc.M109.030700. Epub 2009 Oct 16.

43.

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC, Hodivala-Dilke KM.

Nat Med. 2009 Apr;15(4):392-400. doi: 10.1038/nm.1941. Epub 2009 Mar 22.

PMID:
19305413
44.

The role of cell adhesion pathways in angiogenesis.

Ramjaun AR, Hodivala-Dilke K.

Int J Biochem Cell Biol. 2009 Mar;41(3):521-30. doi: 10.1016/j.biocel.2008.05.030. Epub 2008 Aug 12. Review.

PMID:
18762270
45.

Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis.

Scott AN, Hetheridge C, Reynolds AR, Nayak V, Hodivala-Dilke K, Mellor H.

Angiogenesis. 2008;11(4):337-46. doi: 10.1007/s10456-008-9115-3. Epub 2008 Aug 30.

PMID:
18758974
46.

Integrins: the keys to unlocking angiogenesis.

Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1703-13. doi: 10.1161/ATVBAHA.108.172015. Epub 2008 Jul 24. Review.

PMID:
18658045
47.

alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.

Hodivala-Dilke K.

Curr Opin Cell Biol. 2008 Oct;20(5):514-9. doi: 10.1016/j.ceb.2008.06.007. Epub 2008 Aug 6. Review.

PMID:
18638550
48.

Efficient, inducible Cre-recombinase activation in vascular endothelium.

Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M.

Genesis. 2008 Feb;46(2):74-80. doi: 10.1002/dvg.20367.

PMID:
18257043
49.

alpha3beta1 integrin-controlled Smad7 regulates reepithelialization during wound healing in mice.

Reynolds LE, Conti FJ, Silva R, Robinson SD, Iyer V, Rudling R, Cross B, Nye E, Hart IR, Dipersio CM, Hodivala-Dilke KM.

J Clin Invest. 2008 Mar;118(3):965-74. doi: 10.1172/JCI33538.

50.

Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.

Boosani CS, Mannam AP, Cosgrove D, Silva R, Hodivala-Dilke KM, Keshamouni VG, Sudhakar A.

Blood. 2007 Aug 15;110(4):1168-77. Epub 2007 Apr 10.

Supplemental Content

Loading ...
Support Center